The purpose of this study is to estimate the incidence rate of pure red cell aplasia (PRCA; aplastic anemia) mediated by erythropoietin (EPO) antibodies in patients who are receiving subcutaneous (s.c.) EPREX (polysorbate 80 formulation) for the treatment of anemia associated with chronic renal failure (CRF), and to compare this incidence rate to the incidence rate with s.c. exposure to other currently marketed recombinant erythropoietin products (epoetin alfa, epoetin beta, darbepoetin alfa), with adjustment for duration of exposure. The study will also examine the impact of the patterns of mixed s.c. exposure to multiple erythropoietin products occurring in this subject population, and the impact of the time from exposure to the onset of PRCA.
ERA Safety Registry Study
Chronic Kidney Failure, Pure Red-Cell Aplasia
Natural History, Longitudinal, Defined Population, Prospective Study
This is a multicenter, multinational, immunogenicity surveillance registry using a prospective cohort design (patients identified by a common characteristic), with enrollment of parallel groups that are exposed to the polysorbate 80 formulation of EPREX or other marketed erythropoietin products administered by the s.c. route of administration for the treatment of anemia associated with CRF. The registry is designed to address the following question: Is the current rate of PRCA with the s.c. polysorbate 80 EPREX formulation using coated stoppers similar to the current rate with other marketed erythropoietin products administered by the s.c. route, adjusted for duration of exposure? Each patient will be observed for development of PRCA for up to 3 years. Information on exposure to erythropoietin products, stage of CRF, treatment modality for CRF, erythropoietin handling and storage information, and most recent hemoglobin level will be collected quarterly.
Eligibility & Criteria
- Ages Eligible for Study: 18 Years and above
- Genders Eligible for Study: Both
- Patients with established CRF as an indication for the treatment of anemia
- Patients who are receiving or are about to receive (within 1 month) a marketed erythropoietin product by the s.c. route of administration
- Patients who are likely to continue to receive s.c. erythropoietin product(s) for at least 1 year
- Patients with a history of pure red cell aplasia or aplastic anemia
- Patients who are experiencing unexplained loss or lack of effect to a recombinant erythropoietin product ongoing at the time of enrollment
- Patients who have had prior recombinant erythropoietin treatment whose anemia had never responded (primary lack of efficacy)
- Patients with a history of EPO antibodies prior to enrollment
- Subjects who are currently receiving immunosuppressive medication (e.g. cyclosporine, tacrolimus, sirolimus, mycophenolic mofetil, azathioprine, or monoclonal antibodies) or corticosteroids at a dose corresponding to >15 mg/day prednisolone
- Subjects whose first s.c. exposure to any erythropoietin product was >1 year prior to enrollment
25,000 of which 600 will be Australian.
- Randwick, 2031, Australia; Recruiting
- Perth, 6847, Australia; Recruiting
- Newcastle, 2305, Australia; Recruiting
- Adelaide, 5000, Australia; Recruiting
- Wollongong, 2521, Australia; Recruiting
- Launceston, 7250, Australia; Recruiting
- Hobart, 7000, Australia; Recruiting
- Parkville, 3052, Australia; Recruiting
- Woodville, 5011, Australia; Recruiting
- Liverpool, 2170, Australia; Recruiting
- Perth, 6009, Australia; Recruiting
- Fremantle WA, 6160, Australia; Recruiting
European countries also recruiting. To see if you qualify or for questions on countries other than Australia recruiting, email: email@example.com
All content and media on the HealthEngine Blog is created and published online for informational purposes only. It is not intended to be a substitute for professional medical advice and should not be relied on as health or personal advice. Always seek the guidance of your doctor or other qualified health professional with any questions you may have regarding your health or a medical condition. Never disregard the advice of a medical professional, or delay in seeking it because of something you have read on this Website. If you think you may have a medical emergency, call your doctor, go to the nearest hospital emergency department, or call the emergency services immediately.